NCT03925454 (FREDI-CAL) is a clinical trial in Kidney Failure, sponsored by Portsmouth Hospitals NHS Trust.

Who is sponsoring NCT03925454?

NCT03925454 is sponsored by Portsmouth Hospitals NHS Trust.

What condition does NCT03925454 study?

NCT03925454 studies Kidney Failure.

Is NCT03925454 still recruiting?

NCT03925454 is currently completed. Last updated 7 April 2023.

Last reviewed 2023-04-07 · How we verify

NCT03925454: FREDI-CAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FREquent DIalysis & Markers of Cardiac Strain and Injury, Physical Fitness, Habitual Physical Activity & Quality of Life

Completed Last updated 7 April 2023

What this trial tests

trial in Kidney Failure in 30 participants. Completed in 13 January 2022.

Timeline

19 March 2019

Primary endpoint
13 January 2022

13 January 2022

Quick facts

Lead sponsor	Portsmouth Hospitals NHS Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	19 March 2019
Primary completion	13 January 2022
Estimated completion	13 January 2022
Sites	1 location across United Kingdom

Conditions studied

Kidney Failure — all drugs for Kidney Failure →

Sponsor

Portsmouth Hospitals NHS Trust

Who can join

18 and older, any sex, with Kidney Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Individuals with kidney failure are kept alive using dialysis machines designed to remove toxic substances and excess fluid from the blood. Standard dialysis is undertaken three times a week at a dialysis unit, supported by a team of specialist dialysis nurses (so called in-centre haemodiafiltration or ICHDF). Each session lasts approximately 4 hours, during which time the fluid and toxins which have built up since the last session of treatment are removed from the blood. The rapid removal of fluid that takes place using this technique often causes unpleasant symptoms such as cramps and dizziness, as well as a "hangover", which may last several hours. It can also cause problems with the heart in the long-term. In recent years, individuals requiring dialysis have been able to choose between standard ICHDF or having haemodialysis at home (HHD) using a convenient table top machine called NxStage System One. This device is used more frequently than in ICHDF and for shorter sessions. As a result, the amount of fluid removed during each session is less than with ICHDF. This may be beneficial to the heart, but may also make these individuals feel generally better, which may make them want to be more physically active. It may also reduce the time taken to recover from any symptoms experienced after dialysis. Over a 12 month period, markers of heart damage (using blood tests and scans of the heart) in patients receiving frequent HHD will be studied and the results will be compared with a group of patients receiving ICHDF. The study will also compare any symptoms they may have, how fit they are, how physically active they are and how well they sleep. In addition, the investigators will assess how well fluid balance is maintained in each group and measure the changes in their remaining kidney function during this time.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cardiac dysfunction in dialysing adults with end-stage kidney disease is associated with exercise intolerance: A pilot observational study.
Antoun J, Shepherd AI, Corbett J, Sangala NC, et al · · 2024 · cited 1× · PMID 39256617 · DOI 10.14814/phy2.70050

Verify or expand the search:

Other recruiting trials for Kidney Failure

Currently open trials in the same condition.

NCT07492511 — Renal and Hepatic Abnormal Doppler Patterns in Trauma · recruiting
NCT06243731 — A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation · recruiting
NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
NCT06343727 — A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) · NA · recruiting
NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting

Other Portsmouth Hospitals NHS Trust trials

Trials by the same sponsor.

NCT07426718 — A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Vol · not yet recruiting
NCT07414823 — Walking Football for Axial Spondyloarthritis · NA · active not recruiting
NCT07119203 — Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease · NA · recruiting
NCT07111871 — Healthcare Services for Older People Who Have Fallen With Potential Head Injury · recruiting
NCT07135960 — Breast Cancer BRAs Study (Breast Cancer Biomechanics of Radiotherapy And Surgery) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03925454 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Portsmouth Hospitals NHS Trust
Last refreshed: 7 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03925454.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing